Aim: To analyze the factors that might allow an early discrimination between permanent (P) and transient (T) congenital hypothyroidism (CH). Methods: Clinical, biochemical and imaging data of 64 children with eutopic gland, who were positively screened and treated for CH during the period 1998-2011, were retrospectively analyzed. Results: During a 3-year treatment period, the mean doses of L-thyroxine (L-T4) per kilogram of body weight at various times were significantly lower in the 46 children with T CH than in the remaining 18 with P CH. No patients with T CH had required any increment of the doses of L-T4 per kilogram of body weight to maintain normal thyroid-stimulating hormone levels over time, whereas 16/18 children with P CH during the same period had needed some dose increments (p < 0.0001). Conclusions: (a) L-T4 requirements >4.9 µg/kg/day at 12 months or >4.27 µg/kg/day at 24 months are highly suggestive of P CH, irrespective of gland ultrasonography; (b) L-T4 requirements <1.7 µg/kg/day at 12 months or <1.45 µg/kg/day at 24 months are highly suggestive of T CH, at least in the cases with eutopic gland, and (c) the analysis of L-T4 requirements during the first years of treatment might allow an early discrimination between T and P CH in the cases with eutopic gland.

Keywords:
L-Thyroxine doses, Thyroid function tests, Thyroid scan, Thyroid ultrasonography, Thyrotropin serum levels
1.
Olivieri A, Corbetta C, Weber G, Vigone MC, Fazzini C, Medda E; Italian Study Group for Congenital Hypothyroidism: Congenital hypothyroidism due to defects of thyroid development and mild increase of TSH at screening: data from the Italian National Registry of infants with congenital hypothyroidism. J Clin Endocrinol Metab 2013;98:1403-1408.
2.
Harris KB, Pass KA: Increase in congenital hypothyroidism in New York State and in the United States. Mol Genet Metab 2007;91:268-277.
3.
Olivieri A, Fazzini C, Medda E; Italian Study Group for Congenital Hypothyroidism: Multiple factors influencing the incidence of congenital hypothyroidism detected by neonatal screening. Horm Res Paediatr 2015;83:86-93.
4.
Kemper AR, Ouyang L, Grosse SD: Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data. BMC Pediatr 2010;10:9.
5.
Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G: European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab 2014;99:363-384.
6.
Hong SY, Chung HR, Lee SY, Shin CH, Yang SW: Factors distinguishing between transient and permanent hypothyroidism in patients diagnosed as congenital hypothyroidism by newborn screening. J Korean Soc Pediatr Endocrinol 2005;10:154-160.
7.
Lim HK, Kim KH, Kim SH, No HY, Kim CJ, Woo YJ, Hwang TJ: Predictors of transient hypothyroidism in neonatal screening test. J Korean Soc Pediatr Endocrinol 2006;11:50-56.
8.
Zung A, Tenenbaum-Rakover Y, Barkan S, Hanukoglu A, Hershkovitz E, Pinhas-Hamiel O, Bistritzer T, Zadik Z: Neonatal hyperthyrotropinemia: population characteristics, diagnosis, management and outcome after cessation of therapy. Clin Endocrinol 2010;72:264-271.
9.
Unüvar T, Demir K, Abacı A, Büyükgebiz A, Böber E: The role of initial clinical and laboratory findings in infants with hyperthyrotropinemia to predict transient or permanent hypothyroidism. J Clin Res Pediatr Endocrinol 2013;5:170-173.
10.
Ghasemi M, Hashemipour M, Hovsepian S, Heiydari K, Sajadi A, Hadian R, Mansourian M, Mirshahzadeh N, Dalvi M: Prevalence of transient congenital hypothyroidism in central part of Iran. J Res Med Sci 2013;18:699-703.
11.
Langham S, Hindmarsh P, Krywawych S, Peters C: Screening for congenital hypothyroidism: comparison of borderline screening cut-off points and the effect on the number of children treated with levothyroxine. Eur Thyroid J 2013;2:180-186.
12.
Rabbiosi S, Vigone MC, Cortinovis F, Zamproni I, Fugazzola L, Persani L, Corbetta C, Chiumello G, Weber G: Congenital hypothyroidism with eutopic thyroid gland: analysis of clinical and biochemical features at diagnosis and after re-evaluation. J Clin Endocrinol Metab 2013;98:1395-1402.
13.
Wasniewska M, Salerno M, Cassio A, Corrias A, Aversa T, Zirilli G, Capalbo D, Bal M, Mussa A, De Luca F: Prospective evaluation of the natural course of idiopathic subclinical hypothyroidism in childhood and adolescence. Eur J Endocrinol 2009;160:417-421.
14.
De Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, Cassio A, Mussa A, Aversa T, Radetti G, Arrigo T: Peculiarities of Graves' disease in children and adolescents with Down's syndrome. Eur J Endocrinol 2010;162:591-595.
15.
Wasniewska M, Corrias A, Aversa T, Valenzise M, Mussa A, De Martino L, Lombardo F, De Luca F, Salerno M: Comparative evaluation of therapy with L-thyroxine versus no treatment in children with idiopathic and mild subclinical hypothyroidism. Horm Res Paediatr 2012;77:376-381.
16.
Valenzise M, Aversa T, Corrias A, Mazzanti L, Cappa M, Ubertini G, Scarano E, Mussa A, Messina MF, De Luca F, Wasniewska M: Epidemiology, presentation and long-term evolution of Graves' disease in children, adolescents and young adults with Turner syndrome. Horm Res Paediatr 2014;81:245-250.
17.
Bruno R, Aversa T, Catena M, Valenzise M, Lombardo F, De Luca F, Wasniewska M: Even in the era of congenital hypothyroidism screening mild and subclinical sensorineural hearing loss remains a relatively common complication of severe congenital hypothyroidism. Hear Res 2015;327:43-47.
18.
Cho MS, Cho GS, Park SH, Jung MH, Suh BK, Koh DG: Earlier re-evaluation may be possible in pediatric patients with eutopic congenital hypothyroidism requiring lower L-thyroxine doses. Ann Pediatr Endocrinol Metab 2014;19:141-145.
19.
Delvecchio M, Salerno M, Vigone MC, Wasniewska M, Popolo PP, Lapolla R, Mussa A, Tronconi GM, D'Acunzo I, Di Mase R, Falcone RM, Corrias A, De Luca F, Weber G, Cavallo L, Faienza MF: Levothyroxine requirement in congenital hypothyroidism: a 12-year longitudinal study. Endocrine 2015, Epub ahead of print.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.